HYEX HEALTHY EXTRACTS INC.
Medicinal Chemicals & Botanical Products · OTC · SEC CIK 1630176 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY66.9%
TTM net income YoY-87.1%
TTM EPS YoY—
Revenue 3-yr CAGR31.5%
Net income 3-yr CAGR—
Margins
Gross margin62.4%
Operating margin—
Net margin-36.7%
FCF margin—
EBITDA margin—
Returns
ROE-9.7%
ROA-7.5%
ROIC (approx.)—
Asset turnover0.21x
Leverage & solvency
Liabilities / assets34.0%
Debt / equity0.00x
Current ratio0.14x
Interest coverage—
Cash quality & payout
Operating cash flow / net income-0.33x
Accruals ratio-10.0%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $619,326 | $2.07M | $1.61M | $1.69M | $917,975 | $968,656 | $931,280 | $771,188 |
| Cost of revenue | $280,521 | $614,768 | $622,043 | $736,658 | $470,725 | $375,828 | $506,295 | $356,774 |
| Gross profit | $338,805 | $1.45M | $988,701 | $957,429 | $447,250 | $592,827 | $424,985 | $414,414 |
| SG&A expense | $1.62M | $1.50M | $1.32M | $1.23M | $907,363 | $698,434 | $533,833 | $608,524 |
| Interest expense | $57,117 | -$16,469 | $84,907 | — | — | -$29,559 | $34,558 | — |
| Income tax | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net income | -$1.71M | -$129,389 | -$200,590 | -$153,986 | -$395,394 | $67,120 | -$398,860 | -$446,929 |
| EPS (diluted) | — | — | — | — | — | — | — | — |
| Banking | ||||||||
| Net interest income | -$131,600 | -$106,632 | -$84,907 | -$90,291 | -$56,172 | -$29,259 | -$34,558 | -$54,984 |
| Balance sheet | ||||||||
| Cash & equivalents | $143,267 | $189,958 | $164,385 | $146,935 | $189,452 | $200,494 | $118,798 | $112,020 |
| Receivables | $424,270 | $607,018 | $253,668 | $187,750 | $31,264 | $3,980 | $69,981 | $11,003 |
| Inventory | $572,404 | $644,114 | $520,752 | $843,357 | $966,522 | $1.11M | $1.14M | $1.36M |
| Current assets | $1.29M | $1.68M | $1.09M | $1.33M | $1.73M | $1.56M | $1.48M | $1.66M |
| Goodwill | $26.18M | $26.06M | $21.12M | $21.12M | $193,260 | $193,260 | $193,260 | $193,260 |
| Intangibles | $3.73M | $3.88M | $4.08M | $4.23M | $21,418 | $22,052 | $3,242 | $3,445 |
| Total assets | $32.14M | $32.61M | $27.32M | $27.82M | $26.19M | $2.50M | $2.41M | $2.38M |
| Current liabilities | $9.17M | $8.39M | $1.59M | $1.76M | $1.17M | $861,802 | $2.35M | $1.34M |
| Total liabilities | $10.93M | $10.17M | $3.34M | $3.80M | $2.13M | $2.02M | $2.35M | $1.97M |
| Shareholders' equity | $21.20M | $22.44M | $23.98M | $24.03M | $24.06M | $477,958 | $60,508 | $410,377 |
| Shares outstanding | 15.04M | 14.74M | 16.89M | 16.87M | 16.87M | 3.14M | 2.99M | 2.99M |
| Cash flow statement | ||||||||
| Operating cash flow | -$56,580 | $306,013 | $105,970 | $368,154 | -$279,871 | $17,216 | $60,021 | $41,878 |
| Investing cash flow | -$36,869 | $95,971 | $0 | $75,603 | $0 | -$19,302 | $0 | $0 |
| Financing cash flow | $46,758 | -$376,411 | -$88,520 | -$486,274 | $268,829 | $83,782 | -$53,243 | -$30,260 |
Free plan shows the latest 8 periods; Pro shows all 47 🔒
· This company reports EPS only by share class (e.g. class A/B), so it is shown as —.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.